Abstract: Disclosed herein are systems and uses of systems operating between fully quantum coherent and fully classical states. Examples include a hybrid quantum-classical computing system comprising a plurality of quantum processors connected via classical means.

Abstract: Techniques for diagnosing a patient having an AAA. The techniques include using a computer hardware processor to perform: accessing computed tomography angiography (CTA) images of a portion of the patient, the portion of the patient including the AAA of the patient; providing the CTA images as input to a trained machine learning model, the trained machine learning model being configured to classify a property of the AAA based on the CTA images; and determining, based on the classified property of the AAA, a diagnosis of the patient, the diagnosis including information identifying at least one condition (e.g., an endoleak, an AAA rupture) of the patient.

Abstract: The present invention, in some aspects, relates to systems and methods for determining oxidized proteins, including glutathionylated proteins such as S-glutathionylated proteins. The systems and methods of the invention can be used in vitro (e.g., in cell or tissue culture) or in vivo, for example, to diagnose a person having an oxidative stress condition. For instance, in some cases, the invention can be used to spatially determine the location and/or concentration of oxidized proteins within cells and/or tissues (e.g., through visual detection).

Abstract: The disclosure relates to compounds that demonstrate efficacy in blocking PACAP receptors (e.g. PAC1) and associated methods of treating neurological diseases or disorders using the disclosed compounds. The neurological diseases or disorders include, but are not limited to, stress-related diseases (e.g. chronic stress, post-traumatic stress disorder (PTSD), panic disorder, anxiety, or general anxiety disorder), pain-related diseases (e.g. chronic pain, primary headache disorders, or migraines), or addiction (e.g. addiction to a substance (e.g. addiction to cocaine, amphetamines, methamphetamine, methylphenidate, nicotine, alcohol, prescription medication, marijuana, tobacco, or an opioid selected from heroin, fentanyl, codeine, hydrocodone, morphine, oxycodone, hydromorphone, and methadone)).

Abstract: The present invention has to do with a method and system for peritoneal dialysis catheter weighted anchors. The peritoneal dialysis catheter weighted anchors can be inserted and retrieved using standard techniques and available insertion/retrieval systems. The peritoneal dialysis catheter weighted anchors can be attached and secured to all types of PD catheters as an ancillary anchor device.

Abstract: The present invention has to do with a method and system for preformed peritoneal dialysis (PD) catheter weighted anchors. The peritoneal dialysis catheter weighted anchors can be inserted and retrieved using standard techniques and available insertion/retrieval systems. The peritoneal dialysis catheter weighted anchors can be attached and secured to all types of PD catheters as an ancillary anchor device.

Abstract: The invention features isolated protein complexes and compositions and methods for use thereof. In embodiments, the isolated protein complexes are used for treating conditions associated with reperfusion injury, hypofusion, and/or low/no-reflow. The isolated protein complexes comprise a fusion protein complexed with basic fibroblast growth factor (FGF2), hepatocyte growth factor (HGF), or vascular endothelial growth factor (VEGF). The fusion protein contains an immunoglobulin G (IgG) Fc domain fused to a polypeptide (e.g., Jagged1, a growth factor, or a cytokine).

Abstract: According to some aspects, a cardiac pacemaker for implantation within a subject is provided, the pacemaker including a housing, at least one sensor configured to detect an activity level of the subject, and at least one processor coupled to the sensor configured to detect inactivity of the subject based on output from the at least one sensor, produce a first signal configured to increase the heart rate of the subject to a first heart rate during a first time period, wherein the first heart rate is above a resting heart rate and below 100 beats per minute, and in response to determining that the first time period has elapsed, producing a second signal configured to increase the heart rate of the subject to a second heart rate during a second time period, wherein the second heart rate is between 100 and 140 beats per minute.

Abstract: The invention features methods and compositions for treating a reperfusion injury, hypofusion, ischemic injury, and/or low/no-reflow. In embodiments, the compositions contain complexes containing a basic fibroblast growth factor (FGF2) and an immunoglobulin G (IgG) polypeptide, or fragments thereof. In embodiments, the complexes further contain a hepatocyte growth factor (HGF) polypeptide, a vascular endothelial growth factor (VEGF) polypeptide, or fragments thereof.

Abstract: Compositions and methods involving protein disulfide isomerase (PDI) inhibitors, such as protein disulfide isomerase A3 (PDIA3) inhibitory compounds, for human coronavirus, such as severe acute respiratory syndrome (SARS) virus (e.g., SARS-CoV-2), therapies are disclosed herein.

Abstract: The present invention generally relates to systems and methods for treating certain oxidative stress conditions. In one aspect, compositions and methods of the invention can be used to treat a subject having an oxidative stress condition, for example, a subject having pulmonary fibrosis. In some embodiments, an inhibitor of ERp57 (for example, thiomuscimol) and/or an inhibitor of GSTP (for example, TLK-199) may be used to treat the subject. Also provided in certain aspects of the present invention are kits for such therapies, methods for promoting such therapies, and the like.

Abstract: Methods and kits for detecting cancer-associated miRNA are disclosed herein. Methods of identifying and treating a human patient at risk for cancer are also disclosed herein.

Abstract: Compositions and methods involving protein disulfide isomerase (PDI) inhibitors, such as protein disulfide isomerase A3 (PDIA3) inhibitory compounds, for human coronavirus, such as severe acute respiratory syndrome (SARS) virus (e.g., SARS-CoV-2), therapies are disclosed herein.

Abstract: The invention features compositions featuring (a) one or more of connective tissue growth factor (CTGF) and human C-terminal CTGF peptide; and (b) one or more of insulin and IGF-1; and methods of using such compositions to reduce cardiac tissue damage associated with an ischemic event or to enhance engraftment of a cell in a cardiac tissue.

Abstract: The invention includes, in part, methods and compounds for diagnosing diseases and conditions characterized by altered threonyl-tRNA synthetase (TARS) activity, which include, but are not limited to diseases and conditions in which angiogenesis is altered. In some embodiments of the invention, a level of a TARS molecule is determined and compared to a control level of TARS to assess onset, progression, and/or regression of a disease or condition associated with altered TARS activity.

Abstract: The invention features compositions featuring (a) one or more of connective tissue growth factor (CTGF) and human C-terminal CTGF peptide; and (b) one or more of insulin and IGF-1; and methods of using such compositions to reduce cardiac tissue damage associated with an ischemic event or to enhance engraftment of a cell in a cardiac tissue.

Abstract: Cryptosporidium is a leading contributor to early childhood mortality, and fully effective treatment for this important infectious disease is lacking. A bicyclic azetidine compound series is disclosed having potent in vitro activity against all C. parvum isolates tested, comparable potencies against C. hominis and C. parvum, and cured cryptosporidiosis in highly susceptible immunosuppressed mice with once-daily dosing.

Abstract: Provided herein are compositions and methods relating to ?? T cells. Specifically, methods of screening samples for human ?? T cells surface ligands using a soluble human ?? T cell receptor tetramer are provided. Such ligands may be useful in the treatment of diseases, for example, cancer.

Abstract: Techniques for operating and monitoring an endoscopic balloon dilation system.

Abstract: Techniques for diagnosing a patient having an AAA. The techniques include using a computer hardware processor to perform: accessing computed tomography angiography (CTA) images of a portion of the patient, the portion of the patient including the AAA of the patient; providing the CTA images as input to a trained machine learning model, the trained machine learning model being configured to classify a property of the AAA based on the CTA images; and determining, based on the classified property of the AAA, a diagnosis of the patient, the diagnosis including information identifying at least one condition (e.g., an endoleak, an AAA rupture) of the patient.